-
Sale!
Foundational and emerging principles driving pharmaceutical manufacturing excellence in the digital age. -
Sale!
Comprehensive guide to establishing 16 critical QMS elements aligned with FDA and ICH standards. -
Sale!
14 critical success factors for medical device contract manufacturers including QMS and cybersecurity. -
Sale!
Comprehensive cGMP framework covering quality standards digital transformation and cybersecurity in 2025. -
Sale!
FDA enforcement citation analysis for 21 CFR Part 820 Subpart B – Quality System Requirements (§820.20 Management responsibility, §820.22 Quality audit, §820.25 Personnel). Form 483 observations and Warning Letters 2017–2025. -
Sale!
FDA enforcement citation analysis for 21 CFR Part 820 Subpart C – Design Controls (§820.30). Form 483 observations and Warning Letters 2017–2025. -
Sale!
FDA enforcement citation analysis for 21 CFR Part 820 Subpart D – Document Controls (§820.40). Form 483 observations and Warning Letters 2017–2025. -
Sale!
FDA enforcement citation analysis for 21 CFR Part 820 Subpart E – Purchasing Controls (§820.50). Form 483 observations and Warning Letters 2017–2025. -
Sale!
FDA enforcement citation analysis for 21 CFR Part 820 Subpart G – Production and Process Controls (§820.70, §820.72 Inspection/measuring/test equipment, §820.75 Process validation). Form 483 observations and Warning Letters 2017–2025. -
Sale!
FDA enforcement citation analysis for 21 CFR Part 820 Subpart H – Acceptance Activities (§820.80 Receiving/in-process/finished device acceptance, §820.86 Acceptance status). Form 483 observations and Warning Letters 2017–2025. -
Sale!
FDA enforcement citation analysis for 21 CFR Part 820 Subpart I – Nonconforming Product (§820.90). Form 483 observations and Warning Letters 2017–2025.


